Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

(2012) A. Younes et al.   BLOOD

Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression

(2012) Brian F. Zamarron et al.   International Journal of Biological Sciences

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma

(2011) D. Buglio et al.   BLOOD

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

(2011) T. A. Fehniger et al.   BLOOD

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

(2011) Sylvain Ladoire et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies

(2011) Antonio Gualberto   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment

(2011) Donatella Aldinucci et al.   LEUKEMIA & LYMPHOMA

CD30: an important new target in hematologic malignancies

(2011) Yehuda E. Deutsch et al.   LEUKEMIA & LYMPHOMA

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Classical Hodgkin's lymphoma arising in different host's conditions: Pathobiology parameters, therapeutic options, and outcome

(2010) Antonino Carbone et al.   AMERICAN JOURNAL OF HEMATOLOGY

A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

(2010) B. Sanchez-Espiridion et al.   BLOOD

Blockade of Tumor Necrosis Factor   Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy

(2010) Y. Meng et al.   CANCER RESEARCH

Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes

(2010) K. Movahedi et al.   CANCER RESEARCH

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma

(2010) P. Kamper et al.   HAEMATOLOGICA

Childhood hodgkin's lymphoma, non-hodgkin's lymphoma and factors related to the immune system: The escale study (SFCE)

(2010) Jérémie Rudant et al.   INTERNATIONAL JOURNAL OF CANCER

Histone deacetylase inhibitors in Hodgkin lymphoma

(2010) Daniela Buglio et al.   INVESTIGATIONAL NEW DRUGS

Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes

(2010) Tomás Álvaro et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape

(2010) Donatella Aldinucci et al.   JOURNAL OF PATHOLOGY

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma

(2010) Jessica A. Shafer et al.   LEUKEMIA & LYMPHOMA

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

(2010) Andreas Engert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

(2010) G.-O. Ahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biology and Clinical Applications of CD40 in Cancer Treatment

(2010) Ester Fonsatti et al.   SEMINARS IN ONCOLOGY

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma

(2009) Gaetano Corazzelli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma

(2009) A. Younes et al.   ANNALS OF ONCOLOGY

Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease

(2009) J. A. Rotolo et al.   BLOOD

Hodgkin lymphoma in the Swiss HIV Cohort Study

(2009) G. M. Clifford et al.   BLOOD

High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors

(2009) A. Re et al.   BLOOD

Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab

(2009) L. R. Ambrose et al.   BLOOD

Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma

(2009) A Birgersdotter et al.   BRITISH JOURNAL OF CANCER

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

(2009) Boris Böll et al.   BRITISH JOURNAL OF HAEMATOLOGY

IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma

(2009) Donatella Aldinucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets

(2009) Heiner Adams et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center

(2009) Jason S. Knight et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells

(2009) V. V. Parekh et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

(2009) S. Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Systemic effects of local radiotherapy

(2009) Silvia C Formenti et al.   LANCET ONCOLOGY

Immune infiltration in human tumors: a prognostic factor that should not be ignored

(2009) F Pagès et al.   ONCOGENE

What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?

(2009) C. Robert et al.   ONCOLOGIST

Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases

(2009) Danielle Canioni et al.   PLoS One

Molecular biology of Hodgkin lymphoma

(2009) R. Kuppers   Hematology-American Society of Hematology Education Program

Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells

(2008) Karl R.N. Baumforth et al.   AMERICAN JOURNAL OF PATHOLOGY

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden

(2008) S. Y. Kristinsson et al.   BLOOD

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

(2008) B. Chetaille et al.   BLOOD

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

(2008) Marijke Niens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Expression and function of T cell homing molecules in Hodgkin’s lymphoma

(2008) Lee Machado et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indirect Macrophage Responses to Ionizing Radiation: Implications for Genotype-Dependent Bystander Signaling

(2008) P. J. Coates et al.   CANCER RESEARCH

Tumor-Infiltrated Immune Response Correlates with Alterations in the Apoptotic and Cell Cycle Pathways in Hodgkin and Reed-Sternberg Cells

(2008) T. Alvaro et al.   CLINICAL CANCER RESEARCH

Appraisal of immune response in lymphoproliferative syndromes: A systematic review

(2008) Tomás Álvaro et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Immunogenic anti-cancer chemotherapy as an emerging concept

(2008) Nicole M Haynes et al.   CURRENT OPINION IN IMMUNOLOGY

Immunogenic cancer cell death: a key-lock paradigm

(2008) Antoine Tesniere et al.   CURRENT OPINION IN IMMUNOLOGY

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Macrophages define the invasive microenvironment in breast cancer

(2008) Jeffrey W. Pollard   JOURNAL OF LEUKOCYTE BIOLOGY

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE

Cancer and Immune Response: Old and New Evidence for Future Challenges

(2008) L. de la Cruz-Merino et al.   ONCOLOGIST

Identification of a Small Subpopulation of Candidate Leukemia-Initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia

(2008) Bijan Moshaver et al.   STEM CELLS

HIV-associated Hodgkin lymphoma

(2008) Antonino Carbone et al.   Current Opinion in HIV and AIDS

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

(2007) Yasuhiro Oki et al.   CANCER

Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions

(2007) Donatella Aldinucci et al.   INTERNATIONAL JOURNAL OF CANCER

Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease

(2007) Jan C. Rohr et al.   PEDIATRIC TRANSPLANTATION